Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising

We recently published 10 Power Stocks Crushing Wall Street — 7 at All-Time Highs. Cytokinetics, Inc. (NASDAQ:CYTK) is one of the best performers on Tuesday.

Cytokinetics snapped a two-day losing streak on Tuesday, soaring 40.45 percent to close at $49.62 apiece as investors cheered promising results from its study of Aficamten, its drug candidate for the treatment of obstructive hypertrophic cardiomyopathy (oHCM).

In its presentation to the European Society of Cardiology Congress 2025 in Madrid, Spain over the weekend, Cytokinetics, Inc. (NASDAQ:CYTK) said it found that Aficamten helped oHCM patients exercise better than those who took Metoprolol, which actually dropped exercise abilities.

“The clinical difference in the two treatments is reinforced by the effect of Aficamten on the secondary endpoints. Compared to first-line standard-of-care metoprolol, treatment with Aficamten had a larger effect on measures of symptoms, functional class, and LVOT gradients,” said Fady Malik, executive vice president for research and development at Cytokinetics, Inc. (NASDAQ:CYTK).

Aficamten is an investigational drug candidate currently being reviewed by the US Food and Drug Administration. A decision is expected by December 26, 2025.

While we acknowledge the potential of CYTK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.